NAE1: A promising drug target and biomarker for the prevention and treatment of Alzheimer's disease

Target Name: NAE1

NCBI ID: G8883

NAE1

NAE1: A promising drug target and biomarker for the prevention and treatment of Alzheimer's disease

Alzheimer's disease is a debilitating and progressive neurological disorder that affects millions of people worldwide, primarily in old age. It is characterized by the accumulation of neurofibrillary tangles and senile plaques in the brain, which lead to the destruction of nerve cells and the progressive decline in cognitive and memory functions. Currently, there is no cure for Alzheimer's disease, and the only available treatment is supportive care, which aims to alleviate the symptoms and improve the quality of life of the patients. Therefore, there is a high demand for new treatments that can slow down or even reverse the progression of the disease.

NAE1: A protein with potential as a drug target or biomarker

The discovery of NAE1 (Amyloid beta precursor protein binding protein 1, 59kDa) has raised significant interest as a potential drug target or biomarker for the prevention and treatment of Alzheimer's disease. NAE1 is a protein that is expressed in the brain and has been shown to interact with the amyloid protein, which is a hallmark protein of Alzheimer's disease. The interaction between NAE1 and amyloid has been shown to play a role in the development and progression of the disease.

In addition to its potential as a drug target, NAE1 has also been identified as a potential biomarker for Alzheimer's disease. The presence of NAE1 in brain tissue has been shown to be associated with the level of beta-amyloid protein in the brain, which is a key indicator of the severity of the disease. Furthermore, NAE1 has been shown to be expressed in the brains of individuals with Alzheimer's disease, which further supports its potential as a biomarker for the disease.

The potential benefits of targeting NAE1

Targeting NAE1 as a drug target has the potential to slow down or even reverse the progression of Alzheimer's disease. NAE1 has been shown to interact with amyloid, which is a key protein in the development and progression of the disease. By inhibiting the interaction between NAE1 and amyloid, it may be possible to reduce the formation of beta-amyloid plaques and slow down the progression of the disease.

In addition, NAE1 has also been shown to promote the clearance of beta-amyloid plaques, which may also help to reduce the levels of beta-amyloid protein in the brain and slow down the progression of the disease.

The potential implications of targeting NAE1 have also led to the development of new diagnostic tests for Alzheimer's disease. By using NAE1 as a biomarker, it may be possible to diagnose the disease at an early stage, when treatment is most effective.

The future of NAE1 research

The discovery of NAE1 has opened up new avenues of research into the prevention and treatment of Alzheimer's disease. By targeting NAE1 as a drug target or biomarker, researchers may be able to develop new treatments that can slow down or even reverse the progression of the disease.

In addition, the discovery of NAE1 has also led to the development of new diagnostic tests for Alzheimer's disease. By using NAE1 as a biomarker, researchers may be able to diagnose the disease at an early stage, when treatment is most effective.

Conclusion

NAE1 is a protein that has the potential to slow down or even reverse the progression of Alzheimer's disease. As a drug target or biomarker, NAE1 has the potential to revolutionize the treatment of this debilitating and progressive disorder. Further research is needed to fully understand the role of NAE1 in the development and progression of Alzheimer's disease, and to develop new treatments that can effectively target the protein.

Protein Name: NEDD8 Activating Enzyme E1 Subunit 1

Functions: Regulatory subunit of the dimeric UBA3-NAE1 E1 enzyme. E1 activates NEDD8 by first adenylating its C-terminal glycine residue with ATP, thereafter linking this residue to the side chain of the catalytic cysteine, yielding a NEDD8-UBA3 thioester and free AMP. E1 finally transfers NEDD8 to the catalytic cysteine of UBE2M. Necessary for cell cycle progression through the S-M checkpoint. Overexpression of NAE1 causes apoptosis through deregulation of NEDD8 conjugation

The "NAE1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NAE1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets